Pioneering a Global Cure for Chronic Hepatitis C Virus Infection

Silvia Vilarinho; Richard P Lifton

doi:10.1016/j.cell.2016.08.038

Pioneering a Global Cure for Chronic Hepatitis C Virus Infection

Cell. 2016 Sep 22;167(1):12-15. doi: 10.1016/j.cell.2016.08.038. Epub 2016 Sep 13.

Authors

Silvia Vilarinho¹, Richard P Lifton²

Affiliations

¹ Departments of Genetics and Internal Medicine, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA.
² Departments of Genetics and Internal Medicine, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: richard.lifton@yale.edu.

PMID: 27634325
DOI: 10.1016/j.cell.2016.08.038

Abstract

This year's Lasker∼Debakey Clinical Medical Research Award honors Ralf Bartenschlager, Charles Rice, and Michael Sofia, pioneers in the development of curative and safe therapies for the 170 million people with hepatitis C virus infection.

MeSH terms

Antiviral Agents / therapeutic use
Awards and Prizes*
Clinical Medicine*
Disease Progression
Drug Discovery
End Stage Liver Disease / virology
Hepacivirus* / genetics
Hepacivirus* / isolation & purification
Hepacivirus* / physiology
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / epidemiology
Hepatitis C, Chronic / prevention & control
Humans

Substances

Antiviral Agents